Beam Therapeutics (BEAM) Competitors $27.50 -0.44 (-1.57%) (As of 11/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BEAM vs. NTLA, REPL, SGMO, RGEN, HALO, KRYS, ACLX, ADMA, CRSP, and IMVTShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Intellia Therapeutics (NTLA), Replimune Group (REPL), Sangamo Therapeutics (SGMO), Repligen (RGEN), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), CRISPR Therapeutics (CRSP), and Immunovant (IMVT). These companies are all part of the "medical" sector. Beam Therapeutics vs. Intellia Therapeutics Replimune Group Sangamo Therapeutics Repligen Halozyme Therapeutics Krystal Biotech Arcellx ADMA Biologics CRISPR Therapeutics Immunovant Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Does the media refer more to BEAM or NTLA? In the previous week, Beam Therapeutics had 11 more articles in the media than Intellia Therapeutics. MarketBeat recorded 41 mentions for Beam Therapeutics and 30 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.08 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 9 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, BEAM or NTLA? Beam Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Is BEAM or NTLA more profitable? Intellia Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -41.07%. Beam Therapeutics' return on equity of -16.22% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-41.07% -16.22% -10.94% Intellia Therapeutics N/A -49.34%-40.27% Which has preferable valuation and earnings, BEAM or NTLA? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$377.71M6.03-$132.53M-$1.76-15.63Intellia Therapeutics$43.09M38.08-$481.19M-$5.44-2.96 Do institutionals & insiders have more ownership in BEAM or NTLA? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by insiders. Comparatively, 3.2% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer BEAM or NTLA? Beam Therapeutics presently has a consensus price target of $44.91, indicating a potential upside of 63.31%. Intellia Therapeutics has a consensus price target of $55.36, indicating a potential upside of 243.62%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75Intellia Therapeutics 0 Sell rating(s) 5 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the MarketBeat Community believe in BEAM or NTLA? Intellia Therapeutics received 381 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 69.34% of users gave Intellia Therapeutics an outperform vote while only 54.26% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformBeam TherapeuticsOutperform Votes5154.26% Underperform Votes4345.74% Intellia TherapeuticsOutperform Votes43269.34% Underperform Votes19130.66% SummaryBeam Therapeutics beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Weiss RatingsCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …And one special coin could do even better. Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.28B$3.12B$5.15B$8.94BDividend YieldN/A1.77%5.03%4.03%P/E Ratio-15.6320.9091.9114.61Price / Sales6.03312.801,297.7192.20Price / CashN/A179.8139.3436.42Price / Book2.884.446.425.97Net Income-$132.53M-$42.42M$114.95M$225.00M7 Day Performance3.31%-2.05%-0.76%0.38%1 Month Performance11.25%8.54%4.85%5.73%1 Year Performance25.34%41.85%41.33%31.74% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEAMBeam Therapeutics3.0926 of 5 stars$27.50-1.6%$44.91+63.3%+25.3%$2.28B$377.71M-15.63461Short Interest ↑Analyst RevisionNTLAIntellia Therapeutics4.5778 of 5 stars$17.50+4.6%N/A-32.3%$1.78B$36.28M-3.22600Earnings ReportAnalyst ForecastAnalyst RevisionREPLReplimune Group4.1327 of 5 stars$12.50+0.5%N/A+9.0%$854MN/A-3.82210Earnings ReportAnalyst ForecastNews CoverageGap UpSGMOSangamo Therapeutics2.1582 of 5 stars$2.70-5.9%N/A+707.1%$562.20M$12.28M-1.96480News CoverageGap DownRGENRepligen4.6809 of 5 stars$139.51-0.8%N/A+3.3%$7.81B$638.76M-3,486.881,783Earnings ReportAnalyst UpgradePositive NewsHALOHalozyme Therapeutics4.7872 of 5 stars$61.09+0.2%N/A+56.3%$7.77B$829.25M20.23390Positive NewsKRYSKrystal Biotech4.5709 of 5 stars$195.87-1.9%N/A+84.8%$5.63B$50.70M110.66229ACLXArcellx1.6897 of 5 stars$106.53+3.4%N/A+120.1%$5.54B$110.32M-150.04130Earnings ReportAnalyst ForecastInsider SellingShort Interest ↓ADMAADMA Biologics3.2109 of 5 stars$22.48-0.6%N/A+474.1%$5.27B$258.21M80.29530Earnings ReportOptions VolumeAnalyst RevisionCRSPCRISPR Therapeutics1.6904 of 5 stars$54.86+6.3%N/A-4.3%$4.68B$371.21M-19.39473Insider SellingShort Interest ↑Analyst RevisionGap UpHigh Trading VolumeIMVTImmunovant1.5375 of 5 stars$31.14+1.6%N/A-11.9%$4.56BN/A-14.03120Earnings Report Related Companies and Tools Related Companies NTLA Alternatives REPL Alternatives SGMO Alternatives RGEN Alternatives HALO Alternatives KRYS Alternatives ACLX Alternatives ADMA Alternatives CRSP Alternatives IMVT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BEAM) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
